Cargando…

Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank

BACKGROUND: Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The role of skeletal muscle mass in modulating immune response is well documented. Whilst obesity is well established as a key factor in COVID‐19 and outcome, no study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Thomas J., Yates, Thomas, Baker, Luke A., Zaccardi, Francesco, Smith, Alice C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441916/
https://www.ncbi.nlm.nih.gov/pubmed/34541518
http://dx.doi.org/10.1002/rco2.47
_version_ 1783752922830471168
author Wilkinson, Thomas J.
Yates, Thomas
Baker, Luke A.
Zaccardi, Francesco
Smith, Alice C.
author_facet Wilkinson, Thomas J.
Yates, Thomas
Baker, Luke A.
Zaccardi, Francesco
Smith, Alice C.
author_sort Wilkinson, Thomas J.
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The role of skeletal muscle mass in modulating immune response is well documented. Whilst obesity is well established as a key factor in COVID‐19 and outcome, no study has examined the influence of both sarcopenia (low muscle mass) and obesity, termed ‘sarcopenic obesity’ on the risk of severe COVID‐19. METHODS: This study uses data from UK Biobank. Probable sarcopenia was defined as low handgrip strength. Sarcopenic obesity was mutually exclusively defined as the presence of obesity and low muscle mass [based on two established criteria: appendicular lean mass (ALM) adjusted for either (i) height or (ii) body mass index]. Severe COVID‐19 was defined by a positive severe acute respiratory syndrome coronavirus 2 test result in a hospital setting and/or death with a primary cause reported as COVID‐19. Fully adjusted logistic regression models were used to analyse the associations between sarcopenic status and severe COVID‐19. This work was conducted under UK Biobank Application Number 52553. RESULTS: We analysed data from 490 301 UK Biobank participants (median age 70.0 years, 46% male); 2203 (0.4%) had severe COVID‐19. Individuals with probable sarcopenia were 64% more likely to have had severe COVID‐19 (odds ratio 1.638; P < 0.001). Obesity increased the likelihood of severe COVID‐19 by 76% (P < 0.001). Using either ALM index or ALM/body mass index to define low muscle mass, those with sarcopenic obesity were 2.6 times more likely to have severe COVID‐19 (odds ratio 2.619; P < 0.001). Sarcopenia alone did not increase the risk of COVID‐19. CONCLUSIONS: Sarcopenic obesity may increase the risk of severe COVID‐19, over that of obesity alone. The mechanisms for this are complex but could be a result of a reduction in respiratory functioning, immune response, and ability to respond to metabolic stress.
format Online
Article
Text
id pubmed-8441916
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84419162021-09-15 Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank Wilkinson, Thomas J. Yates, Thomas Baker, Luke A. Zaccardi, Francesco Smith, Alice C. JCSM Rapid Commun Rapid Communication BACKGROUND: Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The role of skeletal muscle mass in modulating immune response is well documented. Whilst obesity is well established as a key factor in COVID‐19 and outcome, no study has examined the influence of both sarcopenia (low muscle mass) and obesity, termed ‘sarcopenic obesity’ on the risk of severe COVID‐19. METHODS: This study uses data from UK Biobank. Probable sarcopenia was defined as low handgrip strength. Sarcopenic obesity was mutually exclusively defined as the presence of obesity and low muscle mass [based on two established criteria: appendicular lean mass (ALM) adjusted for either (i) height or (ii) body mass index]. Severe COVID‐19 was defined by a positive severe acute respiratory syndrome coronavirus 2 test result in a hospital setting and/or death with a primary cause reported as COVID‐19. Fully adjusted logistic regression models were used to analyse the associations between sarcopenic status and severe COVID‐19. This work was conducted under UK Biobank Application Number 52553. RESULTS: We analysed data from 490 301 UK Biobank participants (median age 70.0 years, 46% male); 2203 (0.4%) had severe COVID‐19. Individuals with probable sarcopenia were 64% more likely to have had severe COVID‐19 (odds ratio 1.638; P < 0.001). Obesity increased the likelihood of severe COVID‐19 by 76% (P < 0.001). Using either ALM index or ALM/body mass index to define low muscle mass, those with sarcopenic obesity were 2.6 times more likely to have severe COVID‐19 (odds ratio 2.619; P < 0.001). Sarcopenia alone did not increase the risk of COVID‐19. CONCLUSIONS: Sarcopenic obesity may increase the risk of severe COVID‐19, over that of obesity alone. The mechanisms for this are complex but could be a result of a reduction in respiratory functioning, immune response, and ability to respond to metabolic stress. John Wiley and Sons Inc. 2021-07-03 2022 /pmc/articles/PMC8441916/ /pubmed/34541518 http://dx.doi.org/10.1002/rco2.47 Text en © 2021 The Authors. JCSM Rapid Communications published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Rapid Communication
Wilkinson, Thomas J.
Yates, Thomas
Baker, Luke A.
Zaccardi, Francesco
Smith, Alice C.
Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title_full Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title_fullStr Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title_full_unstemmed Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title_short Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank
title_sort sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from uk biobank
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441916/
https://www.ncbi.nlm.nih.gov/pubmed/34541518
http://dx.doi.org/10.1002/rco2.47
work_keys_str_mv AT wilkinsonthomasj sarcopenicobesityandtheriskofhospitalizationordeathfromcoronavirusdisease2019findingsfromukbiobank
AT yatesthomas sarcopenicobesityandtheriskofhospitalizationordeathfromcoronavirusdisease2019findingsfromukbiobank
AT bakerlukea sarcopenicobesityandtheriskofhospitalizationordeathfromcoronavirusdisease2019findingsfromukbiobank
AT zaccardifrancesco sarcopenicobesityandtheriskofhospitalizationordeathfromcoronavirusdisease2019findingsfromukbiobank
AT smithalicec sarcopenicobesityandtheriskofhospitalizationordeathfromcoronavirusdisease2019findingsfromukbiobank